Literature DB >> 7585191

Complement-specific antibodies: designing novel anti-inflammatories.

L A Matis1, S A Rollins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7585191      PMCID： PMC7095943          DOI： 10.1038/nm0895-839

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  17 in total

Review 1.  Human antibodies from combinatorial libraries.

Authors:  D R Burton; C F Barbas
Journal:  Adv Immunol       Date:  1994       Impact factor: 3.543

Review 2.  Clinical complementology: recent progress and future trends.

Authors:  B P Morgan
Journal:  Eur J Clin Invest       Date:  1994-04       Impact factor: 4.686

3.  beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain.

Authors:  H Jiang; D Burdick; C G Glabe; C W Cotman; A J Tenner
Journal:  J Immunol       Date:  1994-05-15       Impact factor: 5.422

4.  Antigen-specific human antibodies from mice comprising four distinct genetic modifications.

Authors:  N Lonberg; L D Taylor; F A Harding; M Trounstine; K M Higgins; S R Schramm; C C Kuo; R Mashayekh; K Wymore; J G McCabe
Journal:  Nature       Date:  1994-04-28       Impact factor: 49.962

5.  Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

Authors:  J E Tcheng; S G Ellis; B S George; D J Kereiakes; N S Kleiman; J D Talley; A L Wang; H F Weisman; R M Califf; E J Topol
Journal:  Circulation       Date:  1994-10       Impact factor: 29.690

Review 6.  Correlative imaging with monoclonal antibodies in colorectal, ovarian, and prostate cancer.

Authors:  C E Neal; L C Meis
Journal:  Semin Nucl Med       Date:  1994-10       Impact factor: 4.446

Review 7.  Antibody-targeted drugs for the therapy of cancer.

Authors:  G A Pietersz; K Krauer
Journal:  J Drug Target       Date:  1994       Impact factor: 5.121

8.  Direct selection for a catalytic mechanism from combinatorial antibody libraries.

Authors:  K D Janda; C H Lo; T Li; C F Barbas; P Wirsching; R A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

9.  Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs.

Authors:  L L Green; M C Hardy; C E Maynard-Currie; H Tsuda; D M Louie; M J Mendez; H Abderrahim; M Noguchi; D H Smith; Y Zeng; N E David; H Sasai; D Garza; D G Brenner; J F Hales; R P McGuinness; D J Capon; S Klapholz; A Jakobovits
Journal:  Nat Genet       Date:  1994-05       Impact factor: 38.330

10.  Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease.

Authors:  Y Wang; S A Rollins; J A Madri; L A Matis
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205
View more
  17 in total

Review 1.  New therapies in development for autoimmune diseases: their rationale for combination treatment.

Authors:  V Strand
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease.

Authors:  S R Barnum
Journal:  Mol Med       Date:  1999-09       Impact factor: 6.354

Review 3.  Humoral-targeted immunotherapies in multiple sclerosis.

Authors:  Sabeen Lulu; Emmanuelle Waubant
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

4.  The discovery of medicines for rare diseases.

Authors:  David C Swinney; Shuangluo Xia
Journal:  Future Med Chem       Date:  2014-06       Impact factor: 3.808

5.  Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.

Authors:  Anita Hill; Russell P Rother; Louise Arnold; Richard Kelly; Matthew J Cullen; Stephen J Richards; Peter Hillmen
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

6.  Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.

Authors:  Y Wang; Q Hu; J A Madri; S A Rollins; A Chodera; L A Matis
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

7.  Formation of complement membrane attack complex in mammalian cerebral cortex evokes seizures and neurodegeneration.

Authors:  Zhi-Qi Xiong; Weihua Qian; Katsuaki Suzuki; James O McNamara
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

8.  Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents.

Authors:  Antonio M Risitano; Bruno Rotoli
Journal:  Biologics       Date:  2008-06

9.  Targeting of functional antibody-CD59 fusion proteins to a cell surface.

Authors:  H F Zhang; J Yu; E Bajwa; S L Morrison; S Tomlinson
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

10.  Eculizumab in paroxysmal nocturnal haemoglobinuria.

Authors:  Lisa Charneski; Priti N Patel
Journal:  Drugs       Date:  2008       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.